Search

Displaying results 2881 - 2890 of 7540 in total
  1. Drug

    Dipyridamole

    go.drugbank.com/drugs/DB00975
    ApprovedInvestigational

    A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin.

  2. Drug

    Venlafaxine

    go.drugbank.com/drugs/DB00285
    ApprovedInvestigational

    Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. … Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.

    Categories: Anti-Inflammatory Agents, Non-Steroidal
  4. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2).

    Synonyms: SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
  5. Drug

    Sodium phosphate, dibasic

    go.drugbank.com/drugs/DB14502
    ApprovedInvestigational

  6. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.

  7. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects … In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded

  8. Drug

    PH-284

    go.drugbank.com/drugs/DB05452
    Experimental

    Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages. … This binding produces neural impulses that are transmitted by specific pathways to the hypothalamic centre that directly and rapidly affect brain function.

  9. Drug

    Dipivefrin

    go.drugbank.com/drugs/DB00449
    ApprovedWithdrawn

    Dipivefrin is a prodrug of adrenaline, which is used to treat glaucoma. It is available as ophthalmic solution (eye drops).

    Synonyms: (±)-4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate, 4-[1-hydroxy-2-(methylamino)ethyl]-o-phenylene divavalate
  10. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    It is used in the treatment of various dermatoses to relieve pruritus.